Fagron press release

Regulated information Waregem (Belgium)/Rotterdam (Netherlands)¹, 5 August 2015

Fagron issues new shares

As announced on 4 August 2015, Fagron has increased the share capital through the issue of 444,033 new shares within the authorized capital. The new shares will be used for the payment of the earn-out related to the acquisition of Pharmacy Services (acquired in the first quarter of 2014) in the United States. The 444,033 shares will be granted to the current management (former owners) of Pharmacy Services. After these shares have been granted, the management of Pharmacy Services will hold 1.38% of the share capital of Fagron NV.

As of today, the number of Fagron shares with voting rights is 32,111,827. The total number of voting rights (denominator) is 32,111,827. The share capital is € 329,066,194.56.

Fagron profile

Fagron is a scientific pharmaceutical R&D company that is focused on optimizing and innovating customized pharmaceutical care. Fagron provides Fagron Specialty Pharma Services, Fagron Trademarks and Fagron Essentials to pharmacies, clinics and hospitals in 32 countries worldwide.

The Belgian company Fagron NV is located in Waregem and is listed on Euronext Brussels and Euronext Amsterdam. The operational activities of Fagron are driven by the Dutch company Fagron BV. The head office of Fagron BV is located in Rotterdam.

For further information

Jan Peeters
Chief Financial Officer
Tel. +31 88 331 12 52
jan.peeters@fagron.com

Marieke Palstra Global Investor Relations Director Tel. +31 88 331 12 13 marieke.palstra@fagron.com



¹This press release was sent out by Fagron NV and Fagron BV